|Zalicus Initiates Phase 1 Multiple Ascending Dose Study with Z944, a Novel, Oral T-Type Calcium Channel Blocker|
“I am encouraged by the continued progress the
About Z944 and T-type Calcium Channel Blockers
Z944, is a novel, oral, T-type calcium channel blocker that has
demonstrated preclinical efficacy in multiple inflammatory pain models.
A Phase 1 clinical trial evaluating the safety and tolerability of Z944
is ongoing. If Z944 successfully completes this Phase 1 clinical trial,
To learn more about
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995
(c) 2012 Zalicus Inc. All rights reserved.